drugset / Trial / NCT01341470
A Study of LY2495655 in Healthy Subjects
RandomizedSingle-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of LY2495655 administered subcutaneously and intravenously in Japanese subjects.
Timeline
- Start
- 2011-05
- Primary completion
- 2012-05
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LANDOGROZUMAB | Monoclonal antibody | 17.5 mg | Intravenous |
| Subject | LANDOGROZUMAB | Monoclonal antibody | 70 mg | Intravenous |
| Subject | LANDOGROZUMAB | Monoclonal antibody | 140 mg | Intravenous |
| Subject | LANDOGROZUMAB | Monoclonal antibody | 420 mg | Intravenous |
Indications
No indication recorded.